Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs Spry

Invyncible
Graded #303

Higher grade

vs+4.200000000000003
Spry
Graded #409

Lower grade

The verdict

Invyncible takes it — 61/100 to 56.8/100.

Invyncible grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueInvyncible +1
55
54
Dose & formulationEven
64
64
Clinical oversightInvyncible +15
70
55
Labs & monitoringEven
52
52
FulfillmentInvyncible +4
65
61
Contract termsInvyncible +6
61
55
Invyncible · left barSpry · right bar

The numbers

MetricInvyncibleSpry
WeighScore61/10056.8/100
GradeCC
Scorecard rank#303#409
Semaglutide$192/mo (0.5 mg dose, compounded)$199/mo (starting dose, compounded)
Tirzepatide$210/mo (compounded)$299/mo (starting dose, compounded)
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Invyncible

Graded #303 · C

Strengths

  • Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
  • Physical corporate address published (St. Petersburg, FL)
  • LegitScript verification seal displayed
  • No long-term commitment required
  • Offers both semaglutide and tirzepatide programs

Where it loses points

  • Pricing not disclosed on the public site — fully gated behind signup
  • Drug forms (compounded vs brand, injection vs oral) not disclosed
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • States served not listed publicly
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard